Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
14.17
+0.20 (1.43%)
At close: Feb 27, 2026, 4:00 PM EST
14.38
+0.21 (1.48%)
After-hours: Feb 27, 2026, 7:19 PM EST
Aurinia Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Aurinia Pharmaceuticals stock have an average target of 17.25, with a low estimate of 15 and a high estimate of 21. The average target predicts an increase of 21.74% from the current stock price of 14.17.
Analyst Consensus: Buy
* Price targets were last updated on Dec 3, 2025.
Analyst Ratings
The average analyst rating for Aurinia Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $15 → $16 | Buy → Hold | Downgrades | $15 → $16 | +12.91% | Dec 3, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $10 → $21 | Hold → Strong Buy | Upgrades | $10 → $21 | +48.20% | Nov 7, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $9 → $15 | Buy → Hold | Downgrades | $9 → $15 | +5.86% | Nov 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $8 → $9 | Buy | Maintains | $8 → $9 | -36.49% | Aug 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +19.97% | Jul 30, 2025 |
Financial Forecast
Revenue This Year
333.40M
from 283.06M
Increased by 17.79%
Revenue Next Year
385.07M
from 333.40M
Increased by 15.50%
EPS This Year
0.95
from 2.07
Decreased by -53.93%
EPS Next Year
1.09
from 0.95
Increased by 14.44%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 377.5M | 474.6M | |||
| Avg | 333.4M | 385.1M | |||
| Low | 296.5M | 342.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 33.3% | 42.3% | |||
| Avg | 17.8% | 15.5% | |||
| Low | 4.7% | 2.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.40 | 1.79 | |||
| Avg | 0.95 | 1.09 | |||
| Low | 0.63 | 0.44 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -32.5% | 87.2% | |||
| Avg | -53.9% | 14.4% | |||
| Low | -69.7% | -53.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.